Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, MAD Study to Evaluation of Safety, Tolerability and PK of SHR1314 With Axial Spondyloarthritis
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2018
At a glance
- Drugs Vunakizumab (Primary)
- Indications Spondylarthritis
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 18 Oct 2018 New trial record